A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer

James L. Speyer, John Mandeli, Howard Hochster, Carolyn Runowicz, Scott Wadler, Robert Wallach, Carmel Cohen, Dagmar Oette, Joan Sorich, Erin Demakos, Laura Gelpke, Gary Goldberg, Howard Bruckner, James Holland

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The hematopoietic growth factor, recombinant human interleukin-3 (rhu IL-3), stimulates production of both leukocytes and platelets, and thus potentially has greater utility than growth factors that solely stimulate leukocyte production when employed with dose-intensive chemotherapeutic regimens. To determine the optimal schedule for administration of rhu IL-3 in combination with cyclophosphamide and carboplatin, an aggressive regimen for the treatment of advanced ovarian cancer, a phase I trial was initiated by the New York Gynecologic Oncology Group. Following surgical debulking, all patients received cyclophosphamide and carboplatin for 6 cycles. rhu IL-3 was administered at 50, 250, or 500 μg subcutaneously for 5 days either immediately prior to or after administration of chemotherapy. Cohorts of six patients were treated at each dose level (three pre- and three postchemotherapy). Eighteen patients received 91 cycles of treatment. The major toxicities attributable to rhu IL-3 included fevers, chills, malaise, nausea, and headache, but were not dose-limiting at the doses of rhu IL-3 employed. The major finding of this study was that rhu IL-3 administered after chemotherapy offered greater platelet protection than rhu IL-3 administered prior to chemotherapy as assessed by median platelet nadir and duration of platelet counts <50,000/mm3. A second major finding was a dose-response relationship for rhu IL-3: the two higher doses employed, 250 and 500 μ, offered more effective platelet protection than the lower dose employed, 50 μ. rhu IL-3 had no significant effects on leukocyte nadirs or duration of nadirs at any schedule or dose employed. rhu IL-3 may reduce the thrombocytopenia associated with aggressive treatment with cyclophosphamide and carboplatin, although this remains to be confirmed in a randomized, placebo-controlled trial. The effects of rhu IL-3 are dose- and schedule-dependent.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalGynecologic Oncology
Volume56
Issue number3
DOIs
StatePublished - Mar 1995
Externally publishedYes

Fingerprint

Interleukin-3
Ovarian Neoplasms
Carboplatin
Blood Platelets
Cyclophosphamide
Appointments and Schedules
Leukocytes
Drug Therapy
Intercellular Signaling Peptides and Proteins
Chills
Platelet Count
Thrombocytopenia
Nausea
Headache
Fever
Therapeutics
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Speyer, J. L., Mandeli, J., Hochster, H., Runowicz, C., Wadler, S., Wallach, R., ... Holland, J. (1995). A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer. Gynecologic Oncology, 56(3), 387-394. https://doi.org/10.1006/gyno.1995.1068

A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer. / Speyer, James L.; Mandeli, John; Hochster, Howard; Runowicz, Carolyn; Wadler, Scott; Wallach, Robert; Cohen, Carmel; Oette, Dagmar; Sorich, Joan; Demakos, Erin; Gelpke, Laura; Goldberg, Gary; Bruckner, Howard; Holland, James.

In: Gynecologic Oncology, Vol. 56, No. 3, 03.1995, p. 387-394.

Research output: Contribution to journalArticle

Speyer, JL, Mandeli, J, Hochster, H, Runowicz, C, Wadler, S, Wallach, R, Cohen, C, Oette, D, Sorich, J, Demakos, E, Gelpke, L, Goldberg, G, Bruckner, H & Holland, J 1995, 'A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer', Gynecologic Oncology, vol. 56, no. 3, pp. 387-394. https://doi.org/10.1006/gyno.1995.1068
Speyer, James L. ; Mandeli, John ; Hochster, Howard ; Runowicz, Carolyn ; Wadler, Scott ; Wallach, Robert ; Cohen, Carmel ; Oette, Dagmar ; Sorich, Joan ; Demakos, Erin ; Gelpke, Laura ; Goldberg, Gary ; Bruckner, Howard ; Holland, James. / A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer. In: Gynecologic Oncology. 1995 ; Vol. 56, No. 3. pp. 387-394.
@article{fb648421336d464188e13f82937912f5,
title = "A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer",
abstract = "The hematopoietic growth factor, recombinant human interleukin-3 (rhu IL-3), stimulates production of both leukocytes and platelets, and thus potentially has greater utility than growth factors that solely stimulate leukocyte production when employed with dose-intensive chemotherapeutic regimens. To determine the optimal schedule for administration of rhu IL-3 in combination with cyclophosphamide and carboplatin, an aggressive regimen for the treatment of advanced ovarian cancer, a phase I trial was initiated by the New York Gynecologic Oncology Group. Following surgical debulking, all patients received cyclophosphamide and carboplatin for 6 cycles. rhu IL-3 was administered at 50, 250, or 500 μg subcutaneously for 5 days either immediately prior to or after administration of chemotherapy. Cohorts of six patients were treated at each dose level (three pre- and three postchemotherapy). Eighteen patients received 91 cycles of treatment. The major toxicities attributable to rhu IL-3 included fevers, chills, malaise, nausea, and headache, but were not dose-limiting at the doses of rhu IL-3 employed. The major finding of this study was that rhu IL-3 administered after chemotherapy offered greater platelet protection than rhu IL-3 administered prior to chemotherapy as assessed by median platelet nadir and duration of platelet counts <50,000/mm3. A second major finding was a dose-response relationship for rhu IL-3: the two higher doses employed, 250 and 500 μ, offered more effective platelet protection than the lower dose employed, 50 μ. rhu IL-3 had no significant effects on leukocyte nadirs or duration of nadirs at any schedule or dose employed. rhu IL-3 may reduce the thrombocytopenia associated with aggressive treatment with cyclophosphamide and carboplatin, although this remains to be confirmed in a randomized, placebo-controlled trial. The effects of rhu IL-3 are dose- and schedule-dependent.",
author = "Speyer, {James L.} and John Mandeli and Howard Hochster and Carolyn Runowicz and Scott Wadler and Robert Wallach and Carmel Cohen and Dagmar Oette and Joan Sorich and Erin Demakos and Laura Gelpke and Gary Goldberg and Howard Bruckner and James Holland",
year = "1995",
month = "3",
doi = "10.1006/gyno.1995.1068",
language = "English (US)",
volume = "56",
pages = "387--394",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer

AU - Speyer, James L.

AU - Mandeli, John

AU - Hochster, Howard

AU - Runowicz, Carolyn

AU - Wadler, Scott

AU - Wallach, Robert

AU - Cohen, Carmel

AU - Oette, Dagmar

AU - Sorich, Joan

AU - Demakos, Erin

AU - Gelpke, Laura

AU - Goldberg, Gary

AU - Bruckner, Howard

AU - Holland, James

PY - 1995/3

Y1 - 1995/3

N2 - The hematopoietic growth factor, recombinant human interleukin-3 (rhu IL-3), stimulates production of both leukocytes and platelets, and thus potentially has greater utility than growth factors that solely stimulate leukocyte production when employed with dose-intensive chemotherapeutic regimens. To determine the optimal schedule for administration of rhu IL-3 in combination with cyclophosphamide and carboplatin, an aggressive regimen for the treatment of advanced ovarian cancer, a phase I trial was initiated by the New York Gynecologic Oncology Group. Following surgical debulking, all patients received cyclophosphamide and carboplatin for 6 cycles. rhu IL-3 was administered at 50, 250, or 500 μg subcutaneously for 5 days either immediately prior to or after administration of chemotherapy. Cohorts of six patients were treated at each dose level (three pre- and three postchemotherapy). Eighteen patients received 91 cycles of treatment. The major toxicities attributable to rhu IL-3 included fevers, chills, malaise, nausea, and headache, but were not dose-limiting at the doses of rhu IL-3 employed. The major finding of this study was that rhu IL-3 administered after chemotherapy offered greater platelet protection than rhu IL-3 administered prior to chemotherapy as assessed by median platelet nadir and duration of platelet counts <50,000/mm3. A second major finding was a dose-response relationship for rhu IL-3: the two higher doses employed, 250 and 500 μ, offered more effective platelet protection than the lower dose employed, 50 μ. rhu IL-3 had no significant effects on leukocyte nadirs or duration of nadirs at any schedule or dose employed. rhu IL-3 may reduce the thrombocytopenia associated with aggressive treatment with cyclophosphamide and carboplatin, although this remains to be confirmed in a randomized, placebo-controlled trial. The effects of rhu IL-3 are dose- and schedule-dependent.

AB - The hematopoietic growth factor, recombinant human interleukin-3 (rhu IL-3), stimulates production of both leukocytes and platelets, and thus potentially has greater utility than growth factors that solely stimulate leukocyte production when employed with dose-intensive chemotherapeutic regimens. To determine the optimal schedule for administration of rhu IL-3 in combination with cyclophosphamide and carboplatin, an aggressive regimen for the treatment of advanced ovarian cancer, a phase I trial was initiated by the New York Gynecologic Oncology Group. Following surgical debulking, all patients received cyclophosphamide and carboplatin for 6 cycles. rhu IL-3 was administered at 50, 250, or 500 μg subcutaneously for 5 days either immediately prior to or after administration of chemotherapy. Cohorts of six patients were treated at each dose level (three pre- and three postchemotherapy). Eighteen patients received 91 cycles of treatment. The major toxicities attributable to rhu IL-3 included fevers, chills, malaise, nausea, and headache, but were not dose-limiting at the doses of rhu IL-3 employed. The major finding of this study was that rhu IL-3 administered after chemotherapy offered greater platelet protection than rhu IL-3 administered prior to chemotherapy as assessed by median platelet nadir and duration of platelet counts <50,000/mm3. A second major finding was a dose-response relationship for rhu IL-3: the two higher doses employed, 250 and 500 μ, offered more effective platelet protection than the lower dose employed, 50 μ. rhu IL-3 had no significant effects on leukocyte nadirs or duration of nadirs at any schedule or dose employed. rhu IL-3 may reduce the thrombocytopenia associated with aggressive treatment with cyclophosphamide and carboplatin, although this remains to be confirmed in a randomized, placebo-controlled trial. The effects of rhu IL-3 are dose- and schedule-dependent.

UR - http://www.scopus.com/inward/record.url?scp=0028954011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028954011&partnerID=8YFLogxK

U2 - 10.1006/gyno.1995.1068

DO - 10.1006/gyno.1995.1068

M3 - Article

C2 - 7705673

AN - SCOPUS:0028954011

VL - 56

SP - 387

EP - 394

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -